SCHEMBL30394611

SCHEMBL30394611

COCCOc1cc2ncnc(-c3ccc(NC(=O)Cc4ccc(C(F)(F)F)cc4)cc3)c2cc1OC

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 3/20 0.54
▸ BRAF P15056 8/20 0.49
▸ RAF1 P04049 6/20 0.49
▸ PDGFRB P09619 5/20 0.49
▸ FLT4 P35916 3/20 0.49
▸ HDAC1 Q13547 1/20 0.47
▸ AURKA O14965 1/20 0.47
▸ CSF1R P07333 3/20 0.47
▸ RET P07949 1/20 0.47
▸ KIT P10721 1/20 0.47
▸ PDGFRA P16234 1/20 0.47
▸ DDR1 Q08345 1/20 0.47
▸ FLT3 P36888 2/20 0.47
▸ AURKB Q96GD4 1/20 0.47
▸ IRAK4 Q9NWZ3 1/20 0.47
▸ EGFR P00533 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29238215 1.00 KDR (0.54) KDRBRAFRAF1PDGFRBFLT4
SCHEMBL29238333 0.97 KDR (0.49) KDRBRAFRAF1PDGFRBFLT4
SCHEMBL30394615 0.97 KDR (0.49) KDRBRAFRAF1PDGFRBFLT4
SCHEMBL26102182 0.93 KDR (0.51) KDRBRAFRAF1PDGFRBFLT4
SCHEMBL26102366 0.93 KDR (0.51) KDRBRAFRAF1PDGFRBFLT4
SCHEMBL26102568 0.90 KDR (0.53) KDRBRAFRAF1PDGFRBFLT4
SCHEMBL30394038 0.90 BRAF (0.48) KDRBRAFRAF1PDGFRBFLT4
SCHEMBL29238227 0.90 BRAF (0.48) KDRBRAFRAF1PDGFRBFLT4
SCHEMBL26102818 0.89 EGFR (0.54) KDRBRAFRAF1PDGFRBFLT4
SCHEMBL26100255 0.89 KDR (0.49) KDRBRAFPDGFRBFLT4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP claimed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN claimed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB KDR 5/4885BRAF 50/4885RAF1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback